B cell therapy in ANCA-associated vasculitis: current and emerging treatment options
- 14 August 2018
- journal article
- review article
- Published by Springer Nature in Nature Reviews Rheumatology
- Vol. 14 (10) , 580-591
Abstract
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is an organ-threatening and life-threatening multi-system autoimmune disease in which B cell-derived ANCAs cause neutrophil activation and endothelial damage, strongly implicating these autoantibodies in the pathogenesis of AAV. B cell depletion with rituximab combined with glucocorticoids is associated with a reduction in ANCA concentrations and with clinical remission in the majority of patients with AAV. However, the safety profile of rituximab is no better than that of conventional therapy with cyclophosphamide, and long-term glucocorticoid treatment is needed to achieve and maintain disease-free remission. A need for new therapies exists to reduce the time to remission, to spare the use of glucocorticoids and to promote long-lasting remission without the risk of relapse. Over the past 20 years, there has been great interest in therapeutically targeting B cell cytokines, such as B cell-activating factor (BAFF), in many autoimmune disease settings. Dual B cell-targeted immunotherapy that combines B cell depletion and BAFF blockade could potentially be more efficacious than targeting either mechanism alone. In this Review, the theoretical background for use of this combination approach in AAV is presented and discussed.Keywords
This publication has 122 references indexed in Scilit:
- BAFF and selection of autoreactive B cellsTrends in Immunology, 2011
- Prolonged effects of short‐term anti‐CD20 B cell depletion therapy in murine systemic lupus erythematosusArthritis & Rheumatism, 2010
- Rituximab versus Cyclophosphamide for ANCA-Associated VasculitisNew England Journal of Medicine, 2010
- A CD8+ T cell transcription signature predicts prognosis in autoimmune diseaseNature Medicine, 2010
- Patients with Wegener’s granulomatosis demonstrate a relative deficiency and functional impairment of T‐regulatory cellsImmunology, 2010
- The clinical course of ANCA small-vessel vasculitis on chronic dialysisKidney International, 2009
- B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humansProceedings of the National Academy of Sciences, 2009
- Tonic B cell antigen receptor signals supply an NF-κB substrate for prosurvival BLyS signalingNature Immunology, 2008
- Single cell analysis of B lymphocytes from Wegener's granulomatosis: B cell receptors display affinity maturation within the granulomatous lesionsClinical and Experimental Immunology, 2008
- Blood Dendritic Cells Interact with Splenic Marginal Zone B Cells to Initiate T-Independent Immune ResponsesImmunity, 2002